The use of MRI scanners from different manufacturers in this study may be perceived as a limitation, despite demonstrating equivalence in interhemispheric connectivity among controls between scanners. However, novel neuroimaging modalities must show robust differences between healthy and clinical populations across scanners to ever be useful as a clinical biomarker, as hospitals/medical centers use scanners from various manufacturers. While attempts were made to limit the influence of multiple comparisons on the results of the statistical analyses (i.e., using false discovery rate alpha correction and cluster thresholding), the present study may still be impacted by false positives due to the large number of voxel by voxel comparisons.
